These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 13680141

  • 21. Dose-response relationships for alendronate treatment in osteoporotic elderly women. Alendronate Elderly Osteoporosis Study Centers.
    Bone HG, Downs RW, Tucci JR, Harris ST, Weinstein RS, Licata AA, McClung MR, Kimmel DB, Gertz BJ, Hale E, Polvino WJ.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):265-74. PubMed ID: 8989272
    [Abstract] [Full Text] [Related]

  • 22. Prevention of bone loss and vertebral fractures in patients with chronic epilepsy--antiepileptic drug and osteoporosis prevention trial.
    Lazzari AA, Dussault PM, Thakore-James M, Gagnon D, Baker E, Davis SA, Houranieh AM.
    Epilepsia; 2013 Nov; 54(11):1997-2004. PubMed ID: 24010637
    [Abstract] [Full Text] [Related]

  • 23. Determinants of one-year response of lumbar bone mineral density to alendronate treatment in elderly Japanese women with osteoporosis.
    Iwamoto J, Takeda T, Sato Y, Uzawa M.
    Yonsei Med J; 2004 Aug 31; 45(4):676-82. PubMed ID: 15344210
    [Abstract] [Full Text] [Related]

  • 24. Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial.
    Barone A, Giusti A, Pioli G, Girasole G, Razzano M, Pizzonia M, Palummeri E, Bianchi G.
    J Am Geriatr Soc; 2007 May 31; 55(5):752-7. PubMed ID: 17493196
    [Abstract] [Full Text] [Related]

  • 25. Efficacy and safety of a once-yearly i.v. Infusion of zoledronic acid 5 mg versus a once-weekly 70-mg oral alendronate in the treatment of male osteoporosis: a randomized, multicenter, double-blind, active-controlled study.
    Orwoll ES, Miller PD, Adachi JD, Brown J, Adler RA, Kendler D, Bucci-Rechtweg C, Readie A, Mesenbrink P, Weinstein RS.
    J Bone Miner Res; 2010 Oct 31; 25(10):2239-50. PubMed ID: 20499357
    [Abstract] [Full Text] [Related]

  • 26. Effects of alendronate on bone density in men with primary and secondary osteoporosis.
    Ho YV, Frauman AG, Thomson W, Seeman E.
    Osteoporos Int; 2000 Oct 31; 11(2):98-101. PubMed ID: 10793867
    [Abstract] [Full Text] [Related]

  • 27. The antifracture efficacy of alendronate.
    Seeman E.
    Int J Clin Pract Suppl; 1999 Apr 31; 101():40-5. PubMed ID: 12675021
    [Abstract] [Full Text] [Related]

  • 28. Intravenous zoledronic acid and oral alendronate in patients with a low trauma fracture: experience from an osteoporosis clinic.
    Craig SJ, Youssef PP, Vaile JH, Sullivan L, Bleasel JF.
    Intern Med J; 2011 Feb 31; 41(2):186-90. PubMed ID: 20214696
    [Abstract] [Full Text] [Related]

  • 29. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 31; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 30. Alendronate and indapamide alone or in combination in the management of hypercalciuria associated with osteoporosis: a randomized controlled trial of two drugs and three treatments.
    Giusti A, Barone A, Pioli G, Girasole G, Siccardi V, Palummeri E, Bianchi G.
    Nephrol Dial Transplant; 2009 May 31; 24(5):1472-7. PubMed ID: 19075192
    [Abstract] [Full Text] [Related]

  • 31. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study.
    Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F.
    Clin Endocrinol (Oxf); 2004 May 31; 60(5):568-75. PubMed ID: 15104559
    [Abstract] [Full Text] [Related]

  • 32. Changes in bone mineral density following discontinuation or continuation of alendronate therapy in glucocorticoid-treated patients: a retrospective, observational study.
    Emkey R, Delmas PD, Goemaere S, Liberman UA, Poubelle PE, Daifotis AG, Verbruggen N, Lombardi A, Czachur M.
    Arthritis Rheum; 2003 Apr 31; 48(4):1102-8. PubMed ID: 12687554
    [Abstract] [Full Text] [Related]

  • 33. Alendronate with calcium and vitamin D supplementation is safe and effective for the treatment of decreased bone mineral density in HIV.
    McComsey GA, Kendall MA, Tebas P, Swindells S, Hogg E, Alston-Smith B, Suckow C, Gopalakrishnan G, Benson C, Wohl DA.
    AIDS; 2007 Nov 30; 21(18):2473-82. PubMed ID: 18025884
    [Abstract] [Full Text] [Related]

  • 34. The effects of daily alendronate, daily calcitonin and alendronate every other day on bone mineral density in osteoporotic men.
    Guven Z, Karadag-Saygi E, Unlu-Ozkan F, Akyuz G.
    Aging Male; 2007 Dec 30; 10(4):197-201. PubMed ID: 18033629
    [Abstract] [Full Text] [Related]

  • 35. Importance of alfacalcidol in clinical conditions characterized by high rate of bone loss.
    Reginster JY, Lecart MP, Richy F.
    J Rheumatol Suppl; 2005 Sep 30; 76():21-5. PubMed ID: 16142847
    [Abstract] [Full Text] [Related]

  • 36. Pretreatment levels of bone turnover and the antifracture efficacy of alendronate: the fracture intervention trial.
    Bauer DC, Garnero P, Hochberg MC, Santora A, Delmas P, Ewing SK, Black DM, Fracture Intervention Research Group.
    J Bone Miner Res; 2006 Feb 30; 21(2):292-9. PubMed ID: 16418785
    [Abstract] [Full Text] [Related]

  • 37. Eighteen Months of Treatment With Subcutaneous Abaloparatide Followed by 6 Months of Treatment With Alendronate in Postmenopausal Women With Osteoporosis: Results of the ACTIVExtend Trial.
    Cosman F, Miller PD, Williams GC, Hattersley G, Hu MY, Valter I, Fitzpatrick LA, Riis BJ, Christiansen C, Bilezikian JP, Black D.
    Mayo Clin Proc; 2017 Feb 30; 92(2):200-210. PubMed ID: 28160873
    [Abstract] [Full Text] [Related]

  • 38. Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study.
    Emkey R, Delmas PD, Bolognese M, Borges JL, Cosman F, Ragi-Eis S, Recknor C, Zerbini CA, Neate C, Sedarati F, Epstein S.
    Clin Ther; 2009 Apr 30; 31(4):751-61. PubMed ID: 19446148
    [Abstract] [Full Text] [Related]

  • 39. Alendronate reduces bone resorption in HIV-associated osteopenia/osteoporosis.
    Guaraldi G, Orlando G, Madeddu G, Vescini F, Ventura P, Campostrini S, Mura MS, Parise N, Caudarella R, Esposito R.
    HIV Clin Trials; 2004 Apr 30; 5(5):269-77. PubMed ID: 15562367
    [Abstract] [Full Text] [Related]

  • 40. Therapeutic equivalence of alendronate 70 mg once-weekly and alendronate 10 mg daily in the treatment of osteoporosis. Alendronate Once-Weekly Study Group.
    Schnitzer T, Bone HG, Crepaldi G, Adami S, McClung M, Kiel D, Felsenberg D, Recker RR, Tonino RP, Roux C, Pinchera A, Foldes AJ, Greenspan SL, Levine MA, Emkey R, Santora AC, Kaur A, Thompson DE, Yates J, Orloff JJ.
    Aging (Milano); 2000 Feb 30; 12(1):1-12. PubMed ID: 10746426
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 8.